Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women
In iron-depleted women without anemia, oral iron supplements induce an increase in serum hepcidin (SHep) that persists for 24 hours, decreasing iron absorption from supplements given later on the same or next day. Consequently, iron absorption from supplements is highest if iron is given on alternat...
Uloženo v:
| Vydáno v: | Haematologica (Roma) Ročník 105; číslo 5; s. 1232 - 1239 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Italy
Ferrata Storti Foundation
01.05.2020
|
| Témata: | |
| ISSN: | 0390-6078, 1592-8721, 1592-8721 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | In iron-depleted women without anemia, oral iron supplements induce an increase in serum hepcidin (SHep) that persists for 24 hours, decreasing iron absorption from supplements given later on the same or next day. Consequently, iron absorption from supplements is highest if iron is given on alternate days. Whether this dosing schedule is also beneficial in women with iron-deficiency anemia (IDA) given high-dose iron supplements is uncertain. The primary objective of this study was to assess whether, in women with IDA, alternate-day administration of 100 and 200 mg iron increases iron absorption compared to consecutive-day iron administration. Secondary objectives were to correlate iron absorption with SHep and iron status parameters. We performed a cross-over iron absorption study in women with IDA (n=19; median hemoglobin 11.5 mg/dL; mean serum ferritin 10 mg/L) who received either 100 or 200 mg iron as ferrous sulfate given at 8 AM on days 2, 3 and 5 labeled with stable iron isotopes 57Fe, 58Fe and 54Fe; after a 16-day incorporation period, the other labeled dose was given at 8 AM on days 23, 24 and 26 (days 2, 3 and 5 of the second period). Iron absorption on days 2 and 3 (consecutive) and day 5 (alternate) was assessed by measuring erythrocyte isotope incorporation. For both doses, SHep was higher on day 3 than on day 2 (
<0.001) or day 5 (
<0.01) with no significant difference between days 2 and 5. Similarly, for both doses, fractional iron absorption (FIA) on days 2 and 5 was 40-50% higher than on day 3 (
<0.001), while absorption on day 2 did not differ significantly from day 5. There was no significant difference in the incidence of gastrointestinal side effects comparing the two iron doses (
=0.105). Alternate day dosing of oral iron supplements in anemic women may be preferable because it sharply increases FIA. If needed, to provide the same total amount of iron with alternate day dosing, twice the daily target dose should be given on alternate days, as total iron absorption from a single dose of 200 mg given on alternate days was approximately twice that from 100 mg given on consecutive days (
<0.001). In IDA, even if hepatic hepcidin expression is strongly suppressed by iron deficiency and erythropoietic drive, the intake of oral iron supplements leads to an acute hepcidin increase for 24 hours. The study was funded by ETH Zürich, Switzerland. This study has been registered at
. |
|---|---|
| AbstractList | In iron-depleted women without anemia, oral iron supplements induce an increase in serum hepcidin (SHep) that persists for 24 hours, decreasing iron absorption from supplements given later on the same or next day. Consequently, iron absorption from supplements is highest if iron is given on alternate days. Whether this dosing schedule is also beneficial in women with iron-deficiency anemia (IDA) given high-dose iron supplements is uncertain. The primary objective of this study was to assess whether, in women with IDA, alternate-day administration of 100 and 200 mg iron increases iron absorption compared to consecutive-day iron administration. Secondary objectives were to correlate iron absorption with SHep and iron status parameters. We performed a cross-over iron absorption study in women with IDA (n=19; median hemoglobin 11.5 mg/dL; mean serum ferritin 10 mg/L) who received either 100 or 200 mg iron as ferrous sulfate given at 8 AM on days 2, 3 and 5 labeled with stable iron isotopes 57Fe, 58Fe and 54Fe; after a 16-day incorporation period, the other labeled dose was given at 8 AM on days 23, 24 and 26 (days 2, 3 and 5 of the second period). Iron absorption on days 2 and 3 (consecutive) and day 5 (alternate) was assessed by measuring erythrocyte isotope incorporation. For both doses, SHep was higher on day 3 than on day 2 (P In iron-depleted women without anemia, oral iron supplements induce an increase in serum hepcidin (SHep) that persists for 24 hours, decreasing iron absorption from supplements given later on the same or next day. Consequently, iron absorption from supplements is highest if iron is given on alternate days. Whether this dosing schedule is also beneficial in women with iron-deficiency anemia (IDA) given high-dose iron supplements is uncertain. The primary objective of this study was to assess whether, in women with IDA, alternate-day administration of 100 and 200 mg iron increases iron absorption compared to consecutive-day iron administration. Secondary objectives were to correlate iron absorption with SHep and iron status parameters. We performed a cross-over iron absorption study in women with IDA (n=19; median hemoglobin 11.5 mg/dL; mean serum ferritin 10 mg/L) who received either 100 or 200 mg iron as ferrous sulfate given at 8 AM on days 2, 3 and 5 labeled with stable iron isotopes 57Fe, 58Fe and 54Fe; after a 16-day incorporation period, the other labeled dose was given at 8 AM on days 23, 24 and 26 (days 2, 3 and 5 of the second period). Iron absorption on days 2 and 3 (consecutive) and day 5 (alternate) was assessed by measuring erythrocyte isotope incorporation. For both doses, SHep was higher on day 3 than on day 2 (P<0.001) or day 5 (P<0.01) with no significant difference between days 2 and 5. Similarly, for both doses, fractional iron absorption (FIA) on days 2 and 5 was 40-50% higher than on day 3 (P<0.001), while absorption on day 2 did not differ significantly from day 5. There was no significant difference in the incidence of gastrointestinal side effects comparing the two iron doses (P=0.105). Alternate day dosing of oral iron supplements in anemic women may be preferable because it sharply increases FIA. If needed, to provide the same total amount of iron with alternate day dosing, twice the daily target dose should be given on alternate days, as total iron absorption from a single dose of 200 mg given on alternate days was approximately twice that from 100 mg given on consecutive days (P<0.001). In IDA, even if hepatic hepcidin expression is strongly suppressed by iron deficiency and erythropoietic drive, the intake of oral iron supplements leads to an acute hepcidin increase for 24 hours. The study was funded by ETH Zürich, Switzerland. This study has been registered at www.clinicaltrials.gov as #NCT03623997. In iron-depleted women without anemia, oral iron supplements induce an increase in serum hepcidin (SHep) that persists for 24 hours, decreasing iron absorption from supplements given later on the same or next day. Consequently, iron absorption from supplements is highest if iron is given on alternate days. Whether this dosing schedule is also beneficial in women with iron-deficiency anemia (IDA) given high-dose iron supplements is uncertain. The primary objective of this study was to assess whether, in women with IDA, alternate-day administration of 100 and 200 mg iron increases iron absorption compared to consecutive-day iron administration. Secondary objectives were to correlate iron absorption with SHep and iron status parameters. We performed a cross-over iron absorption study in women with IDA (n=19; median hemoglobin 11.5 mg/dL; mean serum ferritin 10 mg/L) who received either 100 or 200 mg iron as ferrous sulfate given at 8 AM on days 2, 3 and 5 labeled with stable iron isotopes 57Fe, 58Fe and 54Fe; after a 16-day incorporation period, the other labeled dose was given at 8 AM on days 23, 24 and 26 (days 2, 3 and 5 of the second period). Iron absorption on days 2 and 3 (consecutive) and day 5 (alternate) was assessed by measuring erythrocyte isotope incorporation. For both doses, SHep was higher on day 3 than on day 2 (P<0.001) or day 5 (P<0.01) with no significant difference between days 2 and 5. Similarly, for both doses, fractional iron absorption (FIA) on days 2 and 5 was 40-50% higher than on day 3 (P<0.001), while absorption on day 2 did not differ significantly from day 5. There was no significant difference in the incidence of gastrointestinal side effects comparing the two iron doses (P=0.105). Alternate day dosing of oral iron supplements in anemic women may be preferable because it sharply increases FIA. If needed, to provide the same total amount of iron with alternate day dosing, twice the daily target dose should be given on alternate days, as total iron absorption from a single dose of 200 mg given on alternate days was approximately twice that from 100 mg given on consecutive days (P<0.001). In IDA, even if hepatic hepcidin expression is strongly suppressed by iron deficiency and erythropoietic drive, the intake of oral iron supplements leads to an acute hepcidin increase for 24 hours. The study was funded by ETH Zürich, Switzerland. This study has been registered at www.clinicaltrials.gov as #NCT03623997.In iron-depleted women without anemia, oral iron supplements induce an increase in serum hepcidin (SHep) that persists for 24 hours, decreasing iron absorption from supplements given later on the same or next day. Consequently, iron absorption from supplements is highest if iron is given on alternate days. Whether this dosing schedule is also beneficial in women with iron-deficiency anemia (IDA) given high-dose iron supplements is uncertain. The primary objective of this study was to assess whether, in women with IDA, alternate-day administration of 100 and 200 mg iron increases iron absorption compared to consecutive-day iron administration. Secondary objectives were to correlate iron absorption with SHep and iron status parameters. We performed a cross-over iron absorption study in women with IDA (n=19; median hemoglobin 11.5 mg/dL; mean serum ferritin 10 mg/L) who received either 100 or 200 mg iron as ferrous sulfate given at 8 AM on days 2, 3 and 5 labeled with stable iron isotopes 57Fe, 58Fe and 54Fe; after a 16-day incorporation period, the other labeled dose was given at 8 AM on days 23, 24 and 26 (days 2, 3 and 5 of the second period). Iron absorption on days 2 and 3 (consecutive) and day 5 (alternate) was assessed by measuring erythrocyte isotope incorporation. For both doses, SHep was higher on day 3 than on day 2 (P<0.001) or day 5 (P<0.01) with no significant difference between days 2 and 5. Similarly, for both doses, fractional iron absorption (FIA) on days 2 and 5 was 40-50% higher than on day 3 (P<0.001), while absorption on day 2 did not differ significantly from day 5. There was no significant difference in the incidence of gastrointestinal side effects comparing the two iron doses (P=0.105). Alternate day dosing of oral iron supplements in anemic women may be preferable because it sharply increases FIA. If needed, to provide the same total amount of iron with alternate day dosing, twice the daily target dose should be given on alternate days, as total iron absorption from a single dose of 200 mg given on alternate days was approximately twice that from 100 mg given on consecutive days (P<0.001). In IDA, even if hepatic hepcidin expression is strongly suppressed by iron deficiency and erythropoietic drive, the intake of oral iron supplements leads to an acute hepcidin increase for 24 hours. The study was funded by ETH Zürich, Switzerland. This study has been registered at www.clinicaltrials.gov as #NCT03623997. In iron-depleted women without anemia, oral iron supplements induce an increase in serum hepcidin (SHep) that persists for 24 hours, decreasing iron absorption from supplements given later on the same or next day. Consequently, iron absorption from supplements is highest if iron is given on alternate days. Whether this dosing schedule is also beneficial in women with iron-deficiency anemia (IDA) given high-dose iron supplements is uncertain. The primary objective of this study was to assess whether, in women with IDA, alternate-day administration of 100 and 200 mg iron increases iron absorption compared to consecutive-day iron administration. Secondary objectives were to correlate iron absorption with SHep and iron status parameters. We performed a cross-over iron absorption study in women with IDA (n=19; median hemoglobin 11.5 mg/dL; mean serum ferritin 10 mg/L) who received either 100 or 200 mg iron as ferrous sulfate given at 8 AM on days 2, 3 and 5 labeled with stable iron isotopes 57Fe, 58Fe and 54Fe; after a 16-day incorporation period, the other labeled dose was given at 8 AM on days 23, 24 and 26 (days 2, 3 and 5 of the second period). Iron absorption on days 2 and 3 (consecutive) and day 5 (alternate) was assessed by measuring erythrocyte isotope incorporation. For both doses, SHep was higher on day 3 than on day 2 ( <0.001) or day 5 ( <0.01) with no significant difference between days 2 and 5. Similarly, for both doses, fractional iron absorption (FIA) on days 2 and 5 was 40-50% higher than on day 3 ( <0.001), while absorption on day 2 did not differ significantly from day 5. There was no significant difference in the incidence of gastrointestinal side effects comparing the two iron doses ( =0.105). Alternate day dosing of oral iron supplements in anemic women may be preferable because it sharply increases FIA. If needed, to provide the same total amount of iron with alternate day dosing, twice the daily target dose should be given on alternate days, as total iron absorption from a single dose of 200 mg given on alternate days was approximately twice that from 100 mg given on consecutive days ( <0.001). In IDA, even if hepatic hepcidin expression is strongly suppressed by iron deficiency and erythropoietic drive, the intake of oral iron supplements leads to an acute hepcidin increase for 24 hours. The study was funded by ETH Zürich, Switzerland. This study has been registered at . |
| Author | Zimmermann, Michael B. Brittenham, Gary M. Zeder, Christophe Moretti, Diego Stoffel, Nicole U. |
| AuthorAffiliation | 2 Columbia University, Department of Pediatrics, College of Physicians and Surgeons, New York, NY, USA 1 ETH Zurich, Department of Health Science and Technology, Institute of Food, Nutrition and Health, Laboratory of Human Nutrition, Zürich, Switzerland |
| AuthorAffiliation_xml | – name: 1 ETH Zurich, Department of Health Science and Technology, Institute of Food, Nutrition and Health, Laboratory of Human Nutrition, Zürich, Switzerland – name: 2 Columbia University, Department of Pediatrics, College of Physicians and Surgeons, New York, NY, USA |
| Author_xml | – sequence: 1 givenname: Nicole U. surname: Stoffel fullname: Stoffel, Nicole U. – sequence: 2 givenname: Christophe surname: Zeder fullname: Zeder, Christophe – sequence: 3 givenname: Gary M. surname: Brittenham fullname: Brittenham, Gary M. – sequence: 4 givenname: Diego surname: Moretti fullname: Moretti, Diego – sequence: 5 givenname: Michael B. surname: Zimmermann fullname: Zimmermann, Michael B. |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31413088$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Uk1vFCEYJqbGblf_gTEcvczKADOABxPT-LFJEy96JiwwuzQzsALTphd_u-86bWM9eOL9ep73g-cCncUUPUKvW7JhjPJ3B-MnU9O4oaRVG0qJZOQZWrWdoo0UtD1DK8IUaXoi5Dm6KOWaEEqUEi_QOWt5y4iUK_Rrm1PEZldSPtYA5pDThMt8PI5-8rEWHAreZ2-qz_g21AM2I5gRfOzMHa4HE5e4TbF4O9dws2RcKiHucYg4QIvG-SHYAIzYRD8Fi28T8L9EzwczFv_q_l2jH58_fb_82lx9-7K9_HjVWCZhB9pLOUjqvBMdU1x50lsOPiXMcsUlF93ghFPgdcxQKx0YkvRMup3pKWVrtF14XTLX-pjDZPKdTiboP4GU99rkGuzotaKCEW4H3gnOO06lFaql3a63ivdwauD6sHAd593knYWdshmfkD7NxHDQ-3SjBYB5fyJ4e0-Q08_Zl6qnUKwfR7hMmoumMIHoZA_brdGbv3s9Nnn4QCjgS4HNqZTsh8eSluiTTvSDTvRJJ3rRCcDe_wOzoZqTAGDiMP4f_BtTWMcw |
| CitedBy_id | crossref_primary_10_2147_PPA_S397122 crossref_primary_10_3390_jcm11226843 crossref_primary_10_1016_j_ajcnut_2023_01_022 crossref_primary_10_1002_ppul_26805 crossref_primary_10_1097_MD_0000000000044084 crossref_primary_10_1111_jmwh_13370 crossref_primary_10_3390_cancers15071935 crossref_primary_10_1002_ncp_10899 crossref_primary_10_1111_anae_16579 crossref_primary_10_1002_jpn3_70097 crossref_primary_10_1016_j_jeud_2024_100098 crossref_primary_10_1097_HS9_0000000000000607 crossref_primary_10_3390_nu16193350 crossref_primary_10_1016_j_mcna_2024_04_002 crossref_primary_10_1007_s15036_020_1322_9 crossref_primary_10_1053_j_gastro_2021_03_001 crossref_primary_10_3390_diagnostics14202306 crossref_primary_10_1016_j_soard_2024_08_018 crossref_primary_10_1093_ibd_izad010 crossref_primary_10_1186_s40814_022_01042_y crossref_primary_10_3390_microbiolres12020033 crossref_primary_10_1016_j_conctc_2025_101447 crossref_primary_10_1186_s13023_022_02448_w crossref_primary_10_1111_anae_16605 crossref_primary_10_3390_ijms23031917 crossref_primary_10_1080_17474086_2023_2206556 crossref_primary_10_1111_birt_12519 crossref_primary_10_1111_hae_14535 crossref_primary_10_1177_15598276221129218 crossref_primary_10_1016_j_mam_2020_100865 crossref_primary_10_3390_nu14030452 crossref_primary_10_1007_s10120_022_01318_5 crossref_primary_10_1002_clc_24117 crossref_primary_10_3390_nu17162670 crossref_primary_10_1002_ijgo_14804 crossref_primary_10_1007_s00277_023_05198_2 crossref_primary_10_1111_bjh_20030 crossref_primary_10_3390_nu16223834 crossref_primary_10_3390_nu13103437 crossref_primary_10_1093_ajcn_nqaa174 crossref_primary_10_1007_s12185_025_04048_3 crossref_primary_10_1016_j_heliyon_2024_e32803 crossref_primary_10_1089_whr_2019_0011 crossref_primary_10_3390_cells9061456 crossref_primary_10_1111_imm_13236 crossref_primary_10_1097_MD_0000000000034421 crossref_primary_10_4103_singaporemedj_SMJ_2024_013 crossref_primary_10_1016_j_nurpra_2023_104877 crossref_primary_10_1038_s41598_025_01421_4 crossref_primary_10_3390_nu16213623 crossref_primary_10_1128_spectrum_05273_22 crossref_primary_10_1007_s10620_022_07599_1 crossref_primary_10_3389_fmed_2022_1010897 crossref_primary_10_1093_eurjpc_zwaf018 crossref_primary_10_3390_nu14091936 crossref_primary_10_3390_nu17182964 crossref_primary_10_1002_ncp_10884 crossref_primary_10_1016_j_gofs_2021_01_001 crossref_primary_10_3390_nu15112620 crossref_primary_10_5694_mja2_52429 crossref_primary_10_1136_bmj_2023_075741 crossref_primary_10_1182_bloodadvances_2020003635 crossref_primary_10_1016_S0140_6736_23_00278_7 crossref_primary_10_1007_s00112_023_01902_8 crossref_primary_10_1111_bjh_19268 crossref_primary_10_1007_s40279_020_01360_2 crossref_primary_10_1111_imj_16602 crossref_primary_10_12968_bjon_2022_31_5_280 crossref_primary_10_1007_s40140_020_00385_7 crossref_primary_10_1007_s11695_024_07446_4 crossref_primary_10_3390_nu15143125 crossref_primary_10_36303_JMLSTSA_2020_2_2_56 crossref_primary_10_1007_s00277_019_03871_z crossref_primary_10_1080_07853890_2020_1867323 crossref_primary_10_1136_gutjnl_2021_325210 crossref_primary_10_1016_j_lwt_2023_115365 crossref_primary_10_1177_1358863X231151731 crossref_primary_10_1016_j_jand_2024_09_007 crossref_primary_10_1182_blood_2019003945 crossref_primary_10_1186_s43162_025_00463_4 crossref_primary_10_1002_pbc_28967 crossref_primary_10_1093_jn_nxac003 crossref_primary_10_3390_hemato6030026 crossref_primary_10_1007_s00277_020_04361_3 crossref_primary_10_1007_s00467_022_05743_7 crossref_primary_10_1007_s12288_024_01844_5 crossref_primary_10_1111_ejh_13892 crossref_primary_10_1253_circj_CJ_25_0220 crossref_primary_10_1111_bjh_20243 crossref_primary_10_1007_s12288_025_02018_7 crossref_primary_10_1002_jpn3_70164 crossref_primary_10_1038_s41598_024_65878_5 crossref_primary_10_1016_S0140_6736_20_32594_0 crossref_primary_10_1007_s40262_024_01421_z crossref_primary_10_1038_s41598_023_29034_9 crossref_primary_10_1186_s12889_020_8271_2 crossref_primary_10_3390_antiox9080645 crossref_primary_10_1053_j_gastro_2020_06_046 crossref_primary_10_1186_s13643_023_02400_4 crossref_primary_10_3390_jcm14030948 crossref_primary_10_1016_j_jshs_2024_101009 crossref_primary_10_1182_blood_2022017626 crossref_primary_10_1007_s12630_023_02650_9 crossref_primary_10_1002_jppr_1972 crossref_primary_10_1007_s12288_024_01816_9 crossref_primary_10_5812_aapm_112910 crossref_primary_10_1136_bmjgast_2021_000759 crossref_primary_10_1177_02692163221145729 crossref_primary_10_3390_nu14040736 crossref_primary_10_1002_jppr_1698 crossref_primary_10_1177_02692163221145730 crossref_primary_10_1093_cdn_nzaa152 crossref_primary_10_1080_17461391_2023_2224285 crossref_primary_10_1186_s12884_025_07938_w crossref_primary_10_1016_S2352_3026_21_00137_X crossref_primary_10_1016_j_disamonth_2022_101327 crossref_primary_10_1111_dom_16368 crossref_primary_10_1136_flgastro_2020_101695 crossref_primary_10_1002_ijgo_15270 crossref_primary_10_1002_ejhf_2251 crossref_primary_10_1111_nyas_15062 crossref_primary_10_1007_s11695_022_06256_w crossref_primary_10_1080_17474086_2023_2166925 crossref_primary_10_1016_j_anclin_2022_10_003 |
| ContentType | Journal Article |
| Copyright | Copyright© 2020 Ferrata Storti Foundation. Copyright© 2020 Ferrata Storti Foundation 2020 |
| Copyright_xml | – notice: Copyright© 2020 Ferrata Storti Foundation. – notice: Copyright© 2020 Ferrata Storti Foundation 2020 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.3324/haematol.2019.220830 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Anatomy & Physiology |
| EISSN | 1592-8721 |
| EndPage | 1239 |
| ExternalDocumentID | oai_doaj_org_article_927304cf457445428c79125b6c946019 PMC7193469 31413088 10_3324_haematol_2019_220830 |
| Genre | Journal Article |
| GeographicLocations | Switzerland |
| GeographicLocations_xml | – name: Switzerland |
| GroupedDBID | --- 29I 2WC 53G 5GY 5RE 5VS AAFWJ AAYXX ADBBV AENEX AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BTFSW C1A CITATION CS3 DIK E3Z EBS EJD F5P FRP GROUPED_DOAJ H13 HYE KQ8 OK1 OVT P2P RHI RNS RPM SJN TFS TR2 UDS W8F WOQ WOW CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c3890-2688f82ded753949e06c482d203c4948475fd7d93c453a2c8dc4580638dba6223 |
| IEDL.DBID | DOA |
| ISSN | 0390-6078 1592-8721 |
| IngestDate | Fri Oct 03 12:44:48 EDT 2025 Tue Sep 30 16:56:51 EDT 2025 Thu Jul 10 22:40:31 EDT 2025 Mon Jul 21 05:56:07 EDT 2025 Sat Nov 29 06:32:54 EST 2025 Tue Nov 18 21:37:35 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Language | English |
| License | Copyright© 2020 Ferrata Storti Foundation. https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3890-2688f82ded753949e06c482d203c4948475fd7d93c453a2c8dc4580638dba6223 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors are co-senior authors |
| OpenAccessLink | https://doaj.org/article/927304cf457445428c79125b6c946019 |
| PMID | 31413088 |
| PQID | 2273758620 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_927304cf457445428c79125b6c946019 pubmedcentral_primary_oai_pubmedcentral_nih_gov_7193469 proquest_miscellaneous_2273758620 pubmed_primary_31413088 crossref_primary_10_3324_haematol_2019_220830 crossref_citationtrail_10_3324_haematol_2019_220830 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-05-00 20200501 2020-05-01 |
| PublicationDateYYYYMMDD | 2020-05-01 |
| PublicationDate_xml | – month: 05 year: 2020 text: 2020-05-00 |
| PublicationDecade | 2020 |
| PublicationPlace | Italy |
| PublicationPlace_xml | – name: Italy |
| PublicationTitle | Haematologica (Roma) |
| PublicationTitleAlternate | Haematologica |
| PublicationYear | 2020 |
| Publisher | Ferrata Storti Foundation |
| Publisher_xml | – name: Ferrata Storti Foundation |
| SSID | ssj0020997 |
| Score | 2.6276827 |
| Snippet | In iron-depleted women without anemia, oral iron supplements induce an increase in serum hepcidin (SHep) that persists for 24 hours, decreasing iron absorption... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1232 |
| SubjectTerms | Anemia, Iron-Deficiency - drug therapy Anemia, Iron-Deficiency - etiology Cross-Over Studies Dietary Supplements Female Hepcidins Humans Iron - administration & dosage Iron - metabolism Switzerland |
| Title | Iron absorption from supplements is greater with alternate day than with consecutive day dosing in iron-deficient anemic women |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31413088 https://www.proquest.com/docview/2273758620 https://pubmed.ncbi.nlm.nih.gov/PMC7193469 https://doaj.org/article/927304cf457445428c79125b6c946019 |
| Volume | 105 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1592-8721 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0020997 issn: 0390-6078 databaseCode: DOA dateStart: 19940101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB5BhRAX1AfQpQ8NEuIWmrWd2D62VSuQoOIA0t6ixHboSpBUSRepF357Z5zsahch9dJbEiexZU8y37w-A7wXPvNcIJmQMqi4JMckvElhom3w0jrCCC5S5n_RV1dmNrPf1rb64pywgR54mLgTS_o1Va5WmVYqI7DstCWlXOXOKjImYukeoZ6lMTWaWlwPGuMHlowj0oJD0Zwk9HByXTIZasthh6n9KOhhzoBeU0qRu_9_gPPfvMk1RXS5DS9HBImnw8h34ElodmHvtKHeft_hB4w5ndFZvgvPv46h8z34-7lrGyyrvu3iXwK5sAR73tQzegh7nPf4kyFk6JC9sxgD6fTagL68Q3axD9cdJ2C7Bf8nY4tv2d-A8wa5ZC7xgUkp6I1YNpx5j5Hk4RX8uLz4fv4pGTdfSBxhmDQRuTG1ET54MmissiHNnaJzkUrHlDJKZ7XX3tJZJkvhjKcDwwDIV2VOoOM1bDVtE_YBtawy46q8EplUgSZ8KqfOVLVUdeoIzk1ALme_cCMzOW-Q8asgC4XXrFiuWcFrVgxrNoFk9dTNwMzxwP1nvLCre5lXO14gaStGaSsekrYJvFuKRUHfIQdXaC7bRU-daEm2Vy6oozeDmKy6klOGCsZMQG8I0MZYNlua-XXk-tYEsFVu3z7G4A_ghWBvQUzXPISt224RjuCZ-3M777tjeKpn5jh-Rvc1WB1c |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Iron+absorption+from+supplements+is+greater+with+alternate+day+than+with+consecutive+day+dosing+in+iron-deficient+anemic+women&rft.jtitle=Haematologica+%28Roma%29&rft.au=Stoffel%2C+Nicole+U.&rft.au=Zeder%2C+Christophe&rft.au=Brittenham%2C+Gary+M.&rft.au=Moretti%2C+Diego&rft.date=2020-05-01&rft.issn=0390-6078&rft.eissn=1592-8721&rft.volume=105&rft.issue=5&rft.spage=1232&rft.epage=1239&rft_id=info:doi/10.3324%2Fhaematol.2019.220830&rft.externalDBID=n%2Fa&rft.externalDocID=10_3324_haematol_2019_220830 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0390-6078&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0390-6078&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0390-6078&client=summon |